Bristol-Myers Squibb Company (BMY) said Wednesday its Opdivo drug significantly increased the overall survival of patients with resectable non-small cell lung cancer combined with chemotherapy, compared to those that underwent chemotherapy only.

This was from the company's analysis of the results of its phase 3 Checkmate -816 study, which was a key secondary endpoint of the study. It also builds on the successful primary endpoints of the study with regard to event-free survival and pathological complete response.

Opdivo is a programmed death-1 immune checkpoint inhibitor that is designed to use the body's own immune system to help restore anti-tumor immune response.